You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
太極集團(600129.SH):西南藥業藥品左氧氟沙星氯化鈉注射液擬中標第五批全國藥品集採
格隆匯 06-23 17:36

格隆匯6月23日丨太極集團(600129.SH)公佈,2021年6月23日,公司控股子公司西南藥業股份有限公司(“西南藥業”)參加了聯合採購辦公室組織的第五批全國藥品集中採購的投標工作。西南藥業藥品左氧氟沙星氯化鈉注射液擬中選該次集中採購。擬中標價格分別為33.65元。採購週期為三年。

除上述藥品外,西南藥業藥品鹽酸異丙嗪片也參與了該次集採競標,但未入圍。2020年該藥品銷售收入60.39萬元,佔公司2020年銷售收入的0.005%,不會對公司經營產生重大影響。

西南藥業擬中標的藥品左氧氟沙星氯化鈉注射液於2021年4月獲得國家藥品監督管理局簽發的《藥品註冊證書》,此前無市場銷售。此次藥品集中採購是國家組織的第五批藥品集中帶量採購,左氧氟沙星氯化鈉注射液如確認中標,在採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量,此次擬中標價格具體以聯合採購辦公室公佈的價格為準。若公司後續簽訂購銷合同並實施後,將有利於增強產品競爭力,提高市場佔有率及公司品牌影響力,對公司未來經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account